More COVID-19 Headwinds In 2021 For GlaxoSmithKline
Company Sacrificing Profits To Invest In R&D
Executive Summary
The UK-headquartered company is in transition, investing heavily in biopharma R&D and preparing to spin out its consumer division.
You may also be interested in...
GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
The mRNA Writing On The Wall, GSK Expands CureVac Alliance Into Next-Gen COVID-19 Vaccines
After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.